benzamidomethyl phenyl ether | 82212-42-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzamidomethyl phenyl ether
• 英文别名: 1-(benzamidomethoxy)benzene；N-(phenoxymethyl)benzamide；Benzamide, N-(phenoxymethyl)-
• CAS: 82212-42-8
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.263
• InChiKey: OTLARUWYQBSRNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  马尿酸 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 8.0h， 生成 benzamidomethyl phenyl ether
  参考文献：
  名称：

  1-(N-酰基氨基)烷基三苯基鏻盐的酰胺烷基化性质

  摘要：

  摘要 容易获得的 1-(N-酰基氨基) 烷基三苯基鏻盐在 (i-Pr)2EtN 存在下与氮、硫、磷和氧亲核试剂顺利反应，得到预期的 α-酰胺烷基化产物，通常产率良好或非常好。丙二酸二烷基酯或乙酰乙酸酯的 α-酰胺烷基化需要使用更强的碱 (DBU)，并在微波辐射的影响下获得最佳结果。在 (i-Pr)2EtN 存在下，在微波反应器中成功地进行了烯胺的 α-酰胺烷基化。1-(N-酰基氨基)烷基三苯基鏻盐可被认为是一种新型、方便、有效的α-酰胺烷基化试剂。图形概要

  DOI：

  10.1080/10426507.2012.744014

文献信息

• [EN] BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS<br/>[FR] AGENTS THÉRAPEUTIQUES - 802
  申请人：ASTRAZENECA AB

  公开号：WO2009047558A1

  公开（公告）日：2009-04-16

  A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R1, R2 , R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.

  化合物的分子式（I）或其药用盐，其中R1、R2、R3、R4和m如说明书中所述，用于治疗肥胖和/或糖尿病。
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。
• N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
  申请人：John Varghese

  公开号：US20070213316A1

  公开（公告）日：2007-09-13

  Disclosed are compounds of the formula wherein the variables R N , R C , R 1 , R 25 , R 2 , and R 3 are as defined herein. These compounds have activity as inhibitors of beta-secretase and are therefore useful in treating a variety of discorders such as Alzheimer's Disease.

  本发明揭示了以下式子的化合物：其中变量RN，RC，R1，R25，R2和R3如本文所定义。这些化合物具有抑制β-分泌酶的活性，因此可用于治疗多种疾病，例如阿尔茨海默病。
• Base-mediated homologative rearrangement of nitrogen–oxygen bonds of <i>N</i>-methyl-<i>N</i>-oxyamides
  作者：Monika Malik、Raffaele Senatore、Thierry Langer、Wolfgang Holzer、Vittorio Pace

  DOI：10.1039/d3sc03216g

  日期：——

  controlled basic conditions, the N-methyl group of the same starting materials acts as a competent precursor of the methylene synthon required for the homologation. The logic is levered on the formation of an electrophilic iminium ion (via N–O heterolysis) susceptible to nucleophilic attack by the alkoxide previously expulsed. The procedure documents genuine chemocontrol and flexibility, as judged by the diversity

  由于众所周知的 C(O)-N 官能团对典型 C1 同系剂（例如类胡萝卜素、重氮甲烷、叶立德）的反应性，导致以 N为中心的片段在生成羰基化合物的过程中被挤出，因此正式的 C1 插入N-O键仍然不为人所知。在此，我们记录了N-甲基-N-乙酰胺（对多种O-取代基具有高耐受性）同系转化为N-酰基-N , O-缩醛。在受控的碱性条件下，相同起始材料的N-甲基基团充当同系化所需的亚甲基合成子的有效前体。该逻辑利用了亲电子亚胺离子（通过N-O 杂解）的形成，该离子容易受到先前排出的醇盐的亲核攻击。该程序记录了真正的化学控制和灵活性，根据酰胺和氮关键上取代基的多样性来判断。通过对 D 标记材料进行的实验验证了该机制的基本原理，这些实验明确地将亚甲基片段的起源归因于起始化合物的N-甲基。
• Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them
  申请人：INTERx RESEARCH CORPORATION

  公开号：EP0046270A1

  公开（公告）日：1982-02-24

  Novel transient prodrug forms of bio-affecting phenolic compounds are selected from the group consisting of those having the structural formula (I): wherein X is O, S or NR5 wherein R5 is hydrogen or lower alkyl; R1 is the mono- or polydehydroxylated residue of a non-steroidal bio-affecting phenol, with the proviso that R' is other than a monohydroxylated or didehydroxylated residue of a phenolic, nuclear dihydroxy natural sympathetic or sympathomimetic amine; R2 is selected from the group consisting of straight or branched chain alkyl, aryl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aralkyl, alkaryl, aralkenyl, aralkynyl, alkenylaryl, alkynylaryl, (lower acyloxy)alkyl, and carboxyalkyl; 3- to 8-membered, saturated or unsaturated mono-heterocyclic or polyheterocyclic containing from 1 to 3 of any one or more of the heteroatoms N, S or O; and mono- or polysubstituted derivatives of the above; R3 is hydrogen, lower acyl, cyano, halo(lower alkyl), carbamyl, lower alkylcarbamyl, di(lower alkyl)carbamyl, CH2ONO2, -CH2OCOR2 or any non-heterocyclic member of the group defined by R2 above; and n is at least one and equals the total number of phenolic hydroxyl functions comprising the non-steroidal bioaffecting phenol etherified via a R2COXCH(R3)0-moiety; those having the structural formula (II): wherein X, R', R2 and R3 are as defined above, and n and m are each at least one and the sum of n+m equals the total number of phenolic hydroxyl functions comprising the non-steroidal bioaffecting phenol either etherified via a R2COXCH(R3)0-moiety or esterified via a R2COO-moiety; and the pharmaceutically acceptable acid addition salts, quaternary ammonium salts and N-oxides thereof.

  生物效应酚类化合物的新型瞬效原药形式选自具有结构式(I)的化合物组成的组： 其中 X 是 O、S 或 NR5，其中 R5 是氢或低级烷基；R1 是非类固醇生物效应酚的单羟基或多羟基残基，但 R' 不是酚、核二羟基天然交感胺或拟交感胺的单羟基或双羟基残基；R2 选自直链或支链烷基、芳基、环烷基、烯基、环烯基、炔基、芳烷基、烷芳基、芳烯基、芳炔基、烯芳基、炔芳基、（低级酰氧基）烷基和羧基烷基组成的组；R3 是氢、低级酰基、氰基、卤代（低级烷基）、氨甲酰基、低级烷基氨甲酰 基、二（低级烷基）氨甲酰基、CH2ONO2、-CH2OCOR2 或上述 R2 定义的基团中的任何非杂环成员；且 n 至少为 1，等于通过 R2COXCH(R3)0 子代醚化的非甾体生物作用酚所包含的酚羟基官能团的总数；具有结构式（II）的酚羟基官能团： 其中 X、R'、R2 和 R3 如上文所定义，n 和 m 至少各为 1，且 n+m 之和等于非甾体类生物效应酚通过 R2COXCH(R3)0 子键醚化或通过 R2COO 子键酯化的酚羟基官能团的总数；及其药学上可接受的酸加成盐、季铵盐和 N-氧化物。